Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

to R&D expenses related to the Company's increasing number of

clinical development programs. The net profit over the reported period

amounts to EUR 18.0 million against a loss of EUR16.0 million over the

full year 2007.

- The Company expects to see an increase in its operating

expenses in the second half of the year as it starts to invest in the

Phase III program for microplasmin in back of the eye disease

- As of June 30, 2008, ThromboGenics had EUR 40.4 million in

cash and cash equivalents. This compares to EUR49.3 million on June 30,

2007 and EUR 46.1 million on December 31, 2007. This cash position does

not yet include the upfront payment from Roche of EUR 30 million that

was only received in July 2008.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "ThromboGenics has made excellent progress in the first half of 2008. We have not only seen very promising clinical data with our lead product, microplasmin, but also signed a significant co-development deal with Roche for our unique anti-cancer agent, TB-403. The ability of microplasmin to resolve certain back of the eye conditions coupled with the financial benefits which our alliance with Roche brings, means we are now well-positioned to advance microplasmin into its Phase III clinical development program. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools available to ensure our corporate success."

For the full report of these results please go to http://www.thrombogenics.com

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microp
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER ... expertly narrows down the product choices to a manageable shortlist of bench and ... list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... Aug. 16, 2011 The Society of Interventional ... with an eye toward the future of the ... funding for one medical student conducting preclinical research ... Hughes Medical Institute,s (HHMI) prestigious Medical Research Fellows ...
... Aug. 16, 2011 SironRX Therapeutics, a biotechnology ... and bone healing, announced today a $3.4 million ... Fund.  Additional investors include Cleveland Clinic, JumpStart Inc., ... Fund III, Early Stage Partners, X Gen Ltd. ...
... 15, 2011 A novel microscopy method at the ... scientists probe the reactions that limit widespread deployment of ... technique called electrochemical strain microscopy that enables them to ... cell materials, which may reveal ways to redesign or ...
Cached Biology Technology:Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 2Society of Interventional Radiology Foundation Funds Howard Hughes Medical Institute Award 3SironRX Therapeutics Raises $3.4 Million Series A 2ORNL microscopy generates new view of fuel cells 2
(Date:8/28/2015)... According to a new market ... Type (Pen & Paper Based, Hosted, Biometrics), Service, Application ... Research), Vertical and Region - Global Forecast to 2020", ... grow from USD 2.4 Billion in 2015 to USD ... Rate (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 ... systems, announced today it will unveil its "Guardian S" ... at the National Tactical Officers Association Conference on August ... Guardian S is the first-ever commercially available energetically autonomous ... research and in-field trials and is protected by more ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3
... Cambridge, MA --- The McGovern Institute for Brain Research ... Scolnick Prize in Neuroscience to Jeremy Nathans, a Howard ... and genetics, neuroscience, and opthalmology at Johns Hopkins University ... the Scolnick Prize lecture entitled "The Evolution of Trichromatic ...
... 2009) The Wildlife Conservation Society announced today a ... are unusually resilient to climate change due to improved ... WCS announced the results of the study at the ... week in Phuket, Thailand. The study, published in ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2009-04/sfeb-roc042209.php,">Chinese . ... State University College of Medicine, Hershey, Pennsylvania ... Opioid Growth Factor (OGF, [Met5]-enkephalin), a clinically ... translocation and reliant on the integrity of ...
Cached Biology News:MIT: Jeremy Nathans to deliver Scolnick Prize lecture 2'Super reefs' fend off climate change, study says 2Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals 2Regulation of cell proliferation by the OGF-OGFr axis is dependent on nuclear localization signals 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MW5...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: